Beclobrate

Summary

Beclobrate (CHEMBL152684) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 346.8 Da · C20H23ClO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL152684
Name	Beclobrate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	51348
Molecular formula	C20H23ClO3
Molecular weight	346.8
InChIKey	YWQGBCXVCXMSLJ-UHFFFAOYSA-N

SMILES: CCC(C)(C(=O)OCC)OC1=CC=C(C=C1)CC2=CC=C(C=C2)Cl

IUPAC name: ethyl 2-[4-[(4-chlorophenyl)methyl]phenoxy]-2-methylbutanoate

Also known as: Beclobrate, Beclobrato, BECLOBRATE, beclobrate

Patent coverage: 417 distinct patent families (1,540 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Kappa-type opioid receptor.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).